Xinhua Pharmaceutical's Dyspnea Drug Passes Chinese Regulator's Consistency Evaluation

MT Newswires Live

2025/11/27

Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) said its Epinephrine Hydrochloride Injection passed China's National Medical Products Administration's consistency of quality and efficacy evaluation, a Thursday Hong Kong bourse filing said.

The drug is mainly suitable for treating severe dyspnea caused by bronchospasm, can quickly relieve anaphylactic shock caused by medication, and can be used to prolong the action time of infiltration anesthesia.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2586364247"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586364247\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586364247?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586364247","market":"hk","top_or_hot":-1,"title":"Xinhua Pharmaceutical's Dyspnea Drug Passes Chinese Regulator's Consistency Evaluation","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SXPHF\">Shandong Xinhua</a> Pharmaceutical (HKG:0719, SHE:000756) said its Epinephrine Hydrochloride Injection passed China's National Medical Products Administration's consistency of quality and efficacy evaluation, a Thursday Hong Kong bourse filing said.</p><p>The drug is mainly suitable for treating severe dyspnea caused by bronchospasm, can quickly relieve anaphylactic shock caused by medication, and can be used to prolong the action time of infiltration anesthesia.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xinhua Pharmaceutical's Dyspnea Drug Passes Chinese Regulator's Consistency Evaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXinhua Pharmaceutical's Dyspnea Drug Passes Chinese Regulator's Consistency Evaluation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-27 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SXPHF\">Shandong Xinhua</a> Pharmaceutical (HKG:0719, SHE:000756) said its Epinephrine Hydrochloride Injection passed China's National Medical Products Administration's consistency of quality and efficacy evaluation, a Thursday Hong Kong bourse filing said.</p><p>The drug is mainly suitable for treating severe dyspnea caused by bronchospasm, can quickly relieve anaphylactic shock caused by medication, and can be used to prolong the action time of infiltration anesthesia.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2586364247","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586364247","pubTimestamp":1764244705,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shandong Xinhua Pharmaceutical  said its Epinephrine Hydrochloride Injection passed China's National Medical Products Administration's consistency of quality and efficacy evaluation, a Thursday Hong Kong bourse filing said.The drug is mainly suitable for treating severe dyspnea caused by bronchospasm, can quickly relieve anaphylactic shock caused by medication, and can be used to prolong the action time of infiltration anesthesia.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","00719":"山东新华制药股份","000756":"新华制药","BK0164":"国企混改","BK1515":"抗疫概念","BK1191":"制药"},"translate_title":"新华制药呼吸困难用药通过中国监管机构一致性评价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000756":0.9,"00719":0.9},"content_text":"Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) said its Epinephrine Hydrochloride Injection passed China's National Medical Products Administration's consistency of quality and efficacy evaluation, a Thursday Hong Kong bourse filing said.The drug is mainly suitable for treating severe dyspnea caused by bronchospasm, can quickly relieve anaphylactic shock caused by medication, and can be used to prolong the action time of infiltration anesthesia.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}